Please provide your email address to receive an email when new articles are posted on . Depemokimab’s mechanism of action is similar to mepolizumab. Three adverse events led to discontinuation ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

These include depemokimab for severe asthma and Blenrep for multiple myeloma. Overall, GSK plc (NYSE:GSK) ranks first among the 8 most undervalued healthcare stocks to buy according to analysts.

The RAINIER Study (NCT06496607) is an ongoing Phase IIa clinical trial investigating Solrikitug for adults with asthma. This randomized, double-blind, placebo-controlled study evaluates three dose ...

In other recent news, GSK plc announced that the US Food and Drug Administration has accepted the Biologics License Application for depemokimab, targeting asthma and chronic rhinosinusitis with ...

Next up are hopeful expansions for its antibody-drug conjugate Blenrep and asthma med Nucala, plus a new launch for biologic depemokimab. All five should help the company achieve its recently ...

In other recent news, GSK plc announced that the US Food and Drug Administration has accepted the Biologics License Application for depemokimab, targeting asthma and chronic rhinosinusitis with nasal ...

Targeting the immune system through modulation of cytokine signalling has been a cornerstone of therapeutic innovation for autoimmune diseases over the past 25 years, exemplified by the success of ...

Other planned launches include Blenrep (for multiple myeloma), depemokimab (chronic rhinosinusitis with nasal polyps and asthma with type II inflammation), Nucala (for chronic obstructive ...